EQS News: Marinomed Biotech AG / Key word(s): Strategic company decision Marinomed Biotech AG is examining strategic options for its Carragelose portfolio 12/18/2023 / 08:33 CET/CEST The issuer/publisher is responsible for the content of the announcement. ═════════════════════════════════════════ ═════════ ═════════════════════════════════════════ ═════════ ═════════════════════════════════════════ ═════════ ══════════════ Marinomed Biotech AG examines strategic options for its Carragelose portfolio • Marinomed examines strategic options for the Carragelose business and hires a consultant to approach potential partners • Change in legal regulations for Medical devices creates a favorable market environment for the Carragelose product portfolio • Marinomed will focus on core competencies in research and development as well as the generation of intellectual property (IP) Korneuburg, Austria, December 18, 2023 – Marinomed Biotech AG (VSE:MARI) is reviewing strategic options for its Carragelose business and has engaged an external consultant in this context. A structured process has been started in which Marinomed and the consultant will contact potential partners. This initiative meets an attractive market environment for medical devices that meet the requirements of the new EU Medical Device Regulation (MDR). An important transition period ends in May 2024, which significantly tightens the requirements for medical devices. Products that do not meet these requirements lose their certificate and may no longer be marketed. Carragelose products meet all the necessary requirements for the MDR and are supported by extensive clinical data, including 12 international clinical studies with more than 1000 patients. Carragelose is a unique, patent-protected, broadly effective virus-blocking agent and is currently marketed in a product portfolio for the prophylaxis and treatment of viral respiratory infections. Current clinical data also supports expanding the use of Carragelose in the areas of allergy and eye health, while the potential for additional applications is not yet fully realized. “We have developed our Carragelose from the idea to a product portfolio that has been successfully marketed worldwide. Today we largely leave regulatory and marketing activities to our established partners, with Marinomed supporting them in scientific and patent matters. With this in mind, we continually evaluate this line of business to enable the best future growth. This includes strategic partnerships and considerations of transferring the portfolio to a partner who can further maximize its value,” comments Andreas Grassauer, CEO of Marinomed. “Since our core competencies lie in the generation of intellectual property, we would like to further intensify our activities in the area of the Marinosolv platform. Our full focus is on our leading product candidates Budesolv and Tacrosolv as well as on future innovative medicines. This is also in line with our strategy to develop therapies for diseases with high unmet medical needs.” “Products that meet MDR requirements are generating great interest from companies with a focus on OTC products. Carragelose products are MDR-fit, which underlines that the timing is right to start a structured process. One result could be that this also improves our financial stability and flexibility. At the same time, we are well on the way to renegotiating the structuring of liabilities at the EIB. Our goal of becoming profitable in 2024 remains our top priority,” adds Pascal Schmidt, CFO of Marinomed. Marinomed invites you to a conference call with Q&A session on December 18th at 2:00 p.m. (CET). The conference will be hosted by Andreas Grassauer, CEO, Eva Prieschl-Grassauer, CSO, and Pascal Schmidt, CFO. To register, please follow this link: (1) https://www.c-meeting.com/web3/meetingRegistration/q1m0fKMJc4zs80rHZGTrAw/3DQVEEWL8KF8KV
Once you have registered (see above), please use the information in the confirmation email to access the conference easily and quickly. We recommend joining a few minutes before the conference starts. About Carragelose®: Carragelose® is a sulfated polymer from red algae with a unique, broad spectrum of virus-blocking activity. It is known to be a tolerated, effective and safe agent for the prevention and treatment of viral respiratory diseases. Several clinical and preclinical studies have shown that Carragelose® forms a protective layer on the mucous membrane that prevents viruses from infecting cells. Laboratory studies and clinical data have confirmed that Carragelose® can also prevent the transmission of SARS-CoV-2.(2)^(1)^,(3)(2) Marinomed holds the patent rights to Carragelose® and has Carragelose® for distribution in Europe, North America, Australia and other countries in Asia and Latin America. Marinomed’s Carragelose® portfolio of nasal sprays and throat products can be found at (4) https://www.carragelose.com/en/portfolio/launched-productsthe scientific publications on Carragelose® at (5) https://www.marinomed.com/de/publikationen/wissenschaftliche-publikationen.
About Marinomed Biotech AG Marinomed Biotech AG is an Austrian, science-based biotechnology company with a growing development pipeline and globally marketed therapeutics. The company develops patent-protected, innovative products in the therapeutic areas of immunology and virology based on its Marinosolv® platform and the virus-blocking effect of Carragelose®. The Marinosolv® technology increases the solubility and bioavailability of poorly soluble active ingredients and is used to develop new therapeutics for indications in the area of autoreactive immune diseases. The Virology segment includes Carragelose®-based over-the-counter products for the prevention and treatment of viral upper respiratory tract infections, partnered in more than 40 countries. The company is based in Korneuburg, Austria and is listed on the Prime Market of the Vienna Stock Exchange (VSE:MARI). Further information: (6) https://www.marinomed.com.
Inquiry note Marinomed Biotech AG International media inquiries PR: Lucia Ziegler Metrum Communications: Roland Mayrl T: +43 2262 90300 158 T: +43 664 6126228 E-mail: (7)pr@marinomed.com E-mail: (9)marinomed@metrum.at IR: Stephanie Kniep T: +43 2262 90300 226 E-mail: (8)ir@marinomed.com Disclaimer This press release contains forward-looking statements based on current views, expectations and forecasts of the management of Marinomed Biotech AG about future events based. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described or otherwise expressed or implied by such statements. The current views, expectations and forecasts of the management of Marinomed Biotech AG are influenced by the context of such statements or words as “anticipate”, “believe”, “estimate”, “expect”, “intend”, “plan”, “project” and Recognize “target”. Forward-looking statements speak only as of the date on which they are made. Marinomed Biotech AG undertakes no obligation to update, revise or revise any forward-looking statements contained in this press release, whether as a result of new information, future developments or otherwise. Marinomed, Marinosolv® and Carragelose® are brands of Marinomed AG. The brands are the property of Marinomed Biotech AG or are licensed out to partners in selected countries. (10)^(1) (11)https://www.dovepress.com/efficacy-of-a-nasal-spray-containing-iota-carrageenan-in-the-postexpos-peer-reviewed-fulltext-article- IJGM (12)^(2) (13)https://www.marinomed.com/de/news/marinomed-biotech-ag-informs-about-positive-clinical-results-for-iota-carrageenan-nasal-spray-for -covid-19-praevention-1 ═════════════════════════════════════ ═════ ═════════════════════════════════════════ ═════════ ═════════════════════════════════════════ ═════════ ══════════════════════ 12/18/2023 CET/CEST Publication of a corporate news/financial announcement, transmitted by EQS Group AG. www.eqs.com
═════════════════════════════════════════ ═════════ ═════════════════════════════════════════ ═════════ ═════════════════════════════════════════ ═════════ ══════════════ Language: German Company: Marinomed Biotech AG Hovengasse 25 2100 Korneuburg Austria Telephone: +43 2262 90300 Email: office@marinomed.com
Internet: www.marinomed.com
ISIN: ATMARINOMED6 WKN: A2N9MM Stock exchanges: open market in Berlin, Düsseldorf, Frankfurt, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange (official trading) EQS News ID: 1798443 End of message EQS News Service 1798443 12/18/2023 CET/CEST References Visible links 1. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=b2c851579a2d814c5f43247777b4ccdd&application_id=1798443&site_id=apa_ots_austria&application_name=news
2. file:///appl/crs1/tmp/HTML-FormatExternal-jD6CMs.html#_edn1
3. file:///appl/crs1/tmp/HTML-FormatExternal-jD6CMs.html#_edn2
4. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=bd2a3dda556ab52fe6b2a10b732e7834&application_id=1798443&site_id=apa_ots_austria&application_name=news
5. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=8970ab7396d4631147b0de7b43c3eb73&application_id=1798443&site_id=apa_ots_austria&application_name=news
6. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=b364e041c58da1aeff9758a10a9b0152&application_id=1798443&site_id=apa_ots_austria&application_name=news
7. pr@marinomed.com 8. and@marinomed.com
9. marinomed@metrum.at
10. file:///appl/crs1/tmp/HTML-FormatExternal-jD6CMs.html#_ednref1
11. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=33ccd3741e11d696674979569046f638&application_id=1798443&site_id=apa_ots_austria&application_name=news
12. file:///appl/crs1/tmp/HTML-FormatExternal-jD6CMs.html#_ednref2
13. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=c7c625ec75e8ba4c80a5a9176c5901e0&application_id=1798443&site_id=apa_ots_austria&application_name=news